ARK Genomic Revolution ETF (ARKG)
| Assets | $1.01B |
| Expense Ratio | 0.75% |
| PE Ratio | n/a |
| Shares Out | 43.90M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -27.58% |
| Volume | 6,841,827 |
| Open | 22.80 |
| Previous Close | 22.95 |
| Day's Range | 22.72 - 24.04 |
| 52-Week Low | 22.27 |
| 52-Week High | 34.37 |
| Beta | 1.49 |
| Holdings | 37 |
| Inception Date | Oct 31, 2014 |
About ARKG
Fund Home PageThe ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is issued by ARK.
Top 10 Holdings
56.58% of assets| Name | Symbol | Weight |
|---|---|---|
| Twist Bioscience Corporation | TWST | 9.20% |
| CRISPR Therapeutics AG | CRSP | 7.00% |
| Recursion Pharmaceuticals, Inc. | RXRX | 6.85% |
| Adaptive Biotechnologies Corporation | ADPT | 5.55% |
| Veracyte, Inc. | VCYT | 5.11% |
| Natera, Inc. | NTRA | 5.08% |
| CareDx, Inc | CDNA | 4.77% |
| Beam Therapeutics Inc. | BEAM | 4.59% |
| Guardant Health, Inc. | GH | 4.32% |
| Schrödinger, Inc. | SDGR | 4.11% |
News
Interest Rate Regimes And ARKG: Underperformance Explained
ARKG's top holdings were replaced due to poor performance, highlighting the fund's vulnerability to interest rate changes and high concentration in cash-burning companies. ARKG underperformed signific...
ARKG: A Genomics Play But Active Isn't Adding Value
Genomics is rapidly advancing, shaping our understanding of health, disease, and life itself. Consider investing in the ARK Genomic Revolution ETF for exposure to leading genomics companies. ARKG's ac...
BMO Transfers 3 BMO Mutual Fund ETF Series, Managed by ARK Investment Management, to Cboe Canada
TORONTO--(BUSINESS WIRE)---- $ARKG #Cboe--Cboe Canada is pleased to announce BMO has transferred three BMO mutual fund ETF series, trading under the symbols ARKK, ARKW, and ARKG to Cboe Canada.
Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April
Hello! This week's ETF Wrap digs into the slump in ETF flows in April and investor positioning around commodities as inflation worries persist.
ARKG: Massive Potential, But Not Worth The Risk Yet For These 3 Reasons
ARK Genomic Revolution ETF warrants a hold rating due to multiple roadblocks preventing solid returns, including underdeveloped technology, legal hurdles, and unresolved ethical dilemmas. ARKG has a r...
Cathie Wood Speaks, ARK Investors Should Listen
Cathie Wood criticizes the US Federal Reserve for its monetary policy mistakes and argues that deflation, not inflation, should be the concern. Wood presents charts showing that technologically driven...
China-focused ETFs struggle amid fears of another regulatory ‘crackdown'
Hi! This week's ETF Wrap funds looks at China-focused funds that are struggling in 2024, with Clocktower's chief strategist Marko Papic providing his take on concerns tied to the country.
Analyzing ARKG's Trading Activity In Q3
ARK Genomic Revolution ETF focuses on genomic innovation in sectors such as healthcare, information technology, and energy. The fund's buying and selling activity gives us clues about the degrees of c...
How to Find the Best Biotech ETFs
The best biotech ETFs allow investors a diversified way to play the volatile biotechnology industry. Here's how to find them.
ARKG ETF: An Enticing Play, But Risks Galore
The ARK Genomic Revolution ETF is a $2bn actively managed ETF that focuses on companies leveraging genomics in their products and services. Genomic-based applications have the potential to revolutioni...
Cathie Wood Says ARK Funds Are Seeing Flows Coming Back
ARK Invest CEO and CIO Cathie Wood comments on ARK's fund flows during an interview with Romaine Bostick and Katie Greifeld on "Bloomberg Markets: The Close."
ARKG: A Probable Window Of Opportunity, Depending On Banks And The Fed
Cathie Wood's ARKG provides investors with an opportunity to take advantage of the billion-dollar genomics market. However, it has performed poorly compared to XLV's higher-quality holdings in a perio...
Stocks that are cyclical are going to face severe challenges, says ARK Invest's Cathie Wood
Cathie Wood of ARK Invest joins 'Squawk on the Street' to discuss her thoughts on the tech space, banking crisis and more.
ARKG: Despite A Huge Price Loss In 2022, Not The Right Time To Accumulate
ARK Genomic Revolution ETF invests in small-cap and mid-cap companies engaged in genomic revolution, i.e., in the research of genomic sequencing, analysis, synthesis, or instrumentation. Alpha-generat...
ARKG: Market May Ridicule ARK, But You Shouldn't Ignore Their Genomics ETF
ARK Invest does great deep-dive research. Utilize their insights along with market timing considerations to generate alpha. The performance of ARKG is dictated mostly by interest rate decisions in the...
ARKG: Too Hard To Pin Down, Too Volatile For Comfort
ARKG's objective is compelling and inoffensive, but their current approach to realizing it feels too vague and scattershot. While the larger names in the portfolio do appear to belong, the bulk of the...
ARKG: A Genomic Revolution Fund For Long Term Growth Seeking Investors
In order to realize the full potential of a genomic revolution-themed ETF, like ARKG, investors have to be patient and look for a longer time horizon. ARKG does some effective reshuffling from time to...